M.D. Anderson Cancer Center
To learn if response-adapted, ultra-low dose radiation therapy can help to control MZL. This means participates first receive lower does of radiation therapy and then, based on how the disease responds, may receive higher doses after that.
Primary Objectives: --To evaluate the efficacy of response adapted ultra low dose therapy (4 Gy with additional 12 Gy if needed) as a complete response after completion of the program Secondary Objectives: * To evaluate distant recurrence of marginal zone lymphoma at 24 months * To evaluate in field relapse at 24 months for all patients * To evaluate the efficacy of response adapted ultra low dose therapy (4 Gy with additional 12 Gy if needed) as overall response rate (ORR) after completion of the program * To evaluate overall survival of patients included in the study Exploratory Objectiv…
Inclusion Criteria: * Patients 18 years or older. Because no RT dosing data are currently available on the use of response adapted ultra low dose RT in patients \<18 years of age, children are excluded from this study. * Patients with stage I-II marginal zone lymphoma. Patients with a pathology report consistent with low grade B cell lymphoma, favor marginal zone lymphoma, are included. Other low grade lymphomas including follicular grade I/II and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) are ineligible. * Patients should not be planned for any systemic therapy before…
4 Gy in 2 fractions
Arctuva estimate
Verify or correct the compensation shown for this listing.